Nevertheless, ICS therapy may have limited CV benefits because ICS treatment does not reduce the inflammatory marker levels in systemic circulation (serum levels of C-reactive protein or interleukin 6), and ICS therapy also has little impact on neutrophil inflammatory responses or extracellular matrix remodeling linked to CV disease in COPD [57, 59]. This evidence concerns the gene IL6 and chronic obstructive pulmonary disease.